Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Immunic Inc (IMUX)

Immunic Inc (IMUX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 133,074
  • Shares Outstanding, K 130,465
  • Annual Sales, $ 0 K
  • Annual Income, $ -100,510 K
  • EBIT $ -106 M
  • EBITDA $ -105 M
  • 60-Month Beta 1.58
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.90

Options Overview Details

View History
  • Implied Volatility 290.63% (+142.27%)
  • Historical Volatility 98.16%
  • IV Percentile 48%
  • IV Rank 31.84%
  • IV High 773.64% on 10/21/25
  • IV Low 65.03% on 10/20/25
  • Expected Move (DTE 20) 0.2125 (20.83%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 558
  • Volume Avg (30-Day) 604
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 20,623
  • Open Int (30-Day) 17,777
  • Expected Range 0.8075 to 1.2325

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.11
  • Number of Estimates 6
  • High Estimate -0.07
  • Low Estimate -0.15
  • Prior Year -0.25
  • Growth Rate Est. (year over year) +56.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5727 +78.10%
on 02/05/26
1.2000 -15.00%
on 02/13/26
+0.3978 (+63.93%)
since 01/27/26
3-Month
0.5062 +101.50%
on 12/30/25
1.2000 -15.00%
on 02/13/26
+0.3190 (+45.51%)
since 11/26/25
52-Week
0.5062 +101.50%
on 12/30/25
1.3500 -24.44%
on 03/25/25
-0.1000 (-8.93%)
since 02/27/25

Most Recent Stories

More News
Immunic: Q4 Earnings Snapshot

Immunic: Q4 Earnings Snapshot

IMUX : 1.0200 (+7.63%)
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update

– Top-Line Data from Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Expected by Year-End 2026 –

IMUX : 1.0200 (+7.63%)
Immunic Announces Closing of Oversubscribed Private Placement Financing

– Upfront Proceeds of USD 200 Million, with Potential for up to USD 200 Million in Additional Proceeds –

IMUX : 1.0200 (+7.63%)
Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company

– Upfront Proceeds of USD 200 Million, with Potential for up to USD 200 Million in Additional Proceeds –

IMUX : 1.0200 (+7.63%)
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

– Additional CALLIPER MRI Analyses Show Reductions for Vidofludimus Calcium in Acute and Chronic Inflammatory Disease Activity –

IMUX : 1.0200 (+7.63%)
Immunic Highlights 2025 Accomplishments and Upcoming Milestones

– Completed Enrollment for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected by End of 2026 –

IMUX : 1.0200 (+7.63%)
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December

NEW YORK , Nov. 26, 2025 /PRNewswire/ -- Immunic, Inc.  (Nasdaq: IMUX) , a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and...

IMUX : 1.0200 (+7.63%)
Immunic: Q3 Earnings Snapshot

Immunic: Q3 Earnings Snapshot

IMUX : 1.0200 (+7.63%)
Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

– Key Data Highlighting Vidofludimus Calcium's Therapeutic Potential in Multiple Sclerosis Presented at 41 st Congress of ECTRIMS  –

IMUX : 1.0200 (+7.63%)
Immunic to Participate in Industry and Investor Conferences in November

NEW YORK , Oct. 29, 2025 /PRNewswire/ --  Immunic, Inc.  (Nasdaq: IMUX) , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies...

IMUX : 1.0200 (+7.63%)

Business Summary

Immunic Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis and psoriasis....

See More

Key Turning Points

3rd Resistance Point 1.1652
2nd Resistance Point 1.1053
1st Resistance Point 1.0627
Last Price 1.0200
1st Support Level 0.9602
2nd Support Level 0.9003
3rd Support Level 0.8577

See More

52-Week High 1.3500
Fibonacci 61.8% 1.0277
Last Price 1.0200
Fibonacci 50% 0.9281
Fibonacci 38.2% 0.8285
52-Week Low 0.5062

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar